Immutep (ASX:IMM)
Company Profile
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Immutep.
RELATED STOCKHEAD STORIES
Health Check: It’s ‘nothing personal’ as major US biotech fund calls time on Syntara
Health Check: The endo-metriosis? Proteomics is on the case
Health Check: Amplia shares surge on pancreatic cancer trial results; Immutep offers hope
Closing Bell: Gold shines brightly despite minor market dip
Health Check: Biotechs recover as peace descends on the FDA – for now
Health Check: Bargain hunters flock to 4D Medical’s discounted raising
Health Check: Percheron ‘closes the book’ on failed childhood rare disease program
Health Check: Clinical trials don’t sleigh down for the silly season
Hot Money Monday: 10 ASX stocks with ‘Strong Buy’ recommendations from brokers
Closing Bell: Tech leads and goldies hit hard; Variscan jumps 50pc as Spanish zinc drilling begins
ASX Lunch Wrap: Xero lifts ASX higher; Selfwealth skyrockets after attracting another suitor
Health Check: Experts deliver their verdict on the Healius imaging deal and it’s ‘yeah nah’
Alive and Kicking: Respiri promises breath of life to bottom line after inking US distribution deal
